Previous 10 | Next 10 |
Improvements observed in overall survival, progression-free survival, local tumor control, time to metastases, and tumor response rate Hazard ratios better than 0.5 on all survival and tumor outcome endpoints Combination with SBRT was well tolerated in the active and pla...
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today an...
Completed enrollment in pivotal Phase 3 ROMAN trial for severe oral mucositis (SOM) in patients with head and neck cancer; topline data expected in Q4 2021 Announced near doubling in median overall survival observed in interim analysis of 42-patient placebo-controlled pancreatic...
Topline data expected in the second half of 2021 Triggers $37.5M milestone payment from Blackstone Life Sciences MALVERN, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and c...
MALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today anno...
Galera Therapeutics (GRTX) announces that the first patient has been dosed in the randomized Phase 2b GRECO-2 trial of GC4711 in combination with stereotactic body radiation therapy ((SBRT)) in patients with locally advanced pancreatic cancer ((LAPC)).Enrollment of the first patient in the tr...
Initiation builds on positive overall survival and tumor control data from Phase 1/2 trial Triggers $20M milestone payment from Blackstone Life Sciences 160-patient randomized, multicenter, placebo-controlled trial MALVERN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Gal...
Describes mechanism which sensitizes cancer cells to radiotherapy Supports recent results showing a near doubling of median overall survival observed in patients with pancreatic cancer by combining Galera’s dismutase mimetic with radiation therapy MALVERN, Pa., May ...
Galera Therapeutics (GRTX): Q1 GAAP EPS of -$0.75 beats by $0.06.Cash, cash equivalents, and short-term investments of $57.52M.Press Release For further details see: Galera Therapeutics EPS beats by $0.06
Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21 Recently announced near doubling of median overall survival observed in placebo-controlled pancreatic cancer trial Phase 2b pancreatic cancer trial, GRECO-...
News, Short Squeeze, Breakout and More Instantly...
Galera Therapeutics Inc. Company Name:
GRTX Stock Symbol:
NYSE Market:
Galera Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Nauticus Robotics Inc. (KITT) rose 29.5% to $0.1787 on volume of 92,016,620 shares Freight Technologies Inc. (FRGT) rose 92.0% to $1.2 on volume of 65,878,105 shares Aethlon Medical Inc. (AEMD) rose 68.2% to $0.7379 on volume of 48,98...
A look at the top 10 most actives in the United States ENDRA Life Sciences Inc. (NDRA) rose 88.2% to $0.159999 on volume of 216,555,450 shares Crown Electrokinetics Corp. (CRKN) fell 13.1% to $0.0908 on volume of 52,298,971 shares Actelis Networks Inc (ASNS) rose 591.5% to $3.25 on volume...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...